Uma M Borate, MD

Trials

Studies that name Uma M Borate, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:42 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06523556 · Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

  Uma Borate · recruiting · Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm · principal investigator
• Ph1
  NCT06222580 · SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  Uma Borate · recruiting · Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation · principal investigator
• Ph2
  NCT05641831 · Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

  Uma Borate · recruiting · Clonal Cytopenia of Undetermined Significance · principal investigator
• Ph2
  NCT05379166 · Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

  Uma Borate · active not recruiting · Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.